Who are resistant patients? quality of treatment and disease control

Addictive Disorders and their Treatment

Volumn 13, Issue 3, 2014, Pages 116-124

  Maremmani, Icro ^a,b,c   Maremmani, Angelo G I ^a,c   Lubrano, Sonia ^d   Nardini, Roberto ^d   Dell'Osso, Liliana ^e   Pacini, Matteo ^a,b,d  

^a UNIVERSITY OF PISA   (Italy)

^b G DE LISIO INSTITUTE OF BEHAVIOURAL SCIENCES   (Italy)

^c Association for the Application of Neuroscientific Knowledge to Social Aims AU CNS   (Italy)

^d Project Open Community (PCA)   (Italy)

^e UNIVERSITY OF PISA   (Italy)

Author keywords

drug addiction; effective treatments; quality of assistance; refractoriness

Indexed keywords

METHADONE;

ADULT; ARTICLE; DISEASE COURSE; FEMALE; HEALTH CARE QUALITY; HEALTH SERVICE; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84908356450     PISSN: 15315754     EISSN: None     Source Type: Journal    
DOI: 10.1097/ADT.0000000000000034     Document Type: Article

References (38)

1. Maremmani I, Pacini M. Understanding the patho-genesis of drug addiction in order to implement a correct pharmacological intervention. Heroin Addict Relat Clin Probl. 2003;5:5-12.
2. Strain EC. Patient-treatment matching and opioid addicted patients: past methods and future opportunities. Heroin Addict Relat Clin Probl. 2004;6: 5-16.
3. Vossenberg P. Attitudes and beliefs towards Metha-done of staff working in substance abuse treatment. Heroin Addict Relat Clin Probl. 2000;2:15-21.
4. Addiss SS, Horosko S. Medical mismanagement in public methadone programs. Conn Med. 1994; 58:173-174.
5. Barnett PG, Hui SS. The cost-effectiveness of metha-done maintenance. Mt Sinai J Med. 2000;67:365-374.
6. Avants SK, Margolin A, Sindelar JL, et al. Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost. Am J Psychiatry. 1999;156:27-33.
7. Dijkgraaf MG, van der Zanden BP, de Borgie CA, et al. Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. Br Med J. 2005;4:1297.
8. Newman RG. Methadone: prescribing maintenance, pursuing abstinence. Int J Addict. 1995;30:1303-1309.
9. Newman RG. Discontinuation symptoms are not addiction/dependence [Letter]. Heroin Addict Relat Clin Probl. 2000;2:47-48.
10. Maremmani I, Pacini M, Lubrano S, et al. L'impiego degli alti dosaggi di metadone nella dipendenza da eroina. Medicina delle Tossicodipendenze-Ital J Addict. 2002;10:31-40.
11. Simpson DD. Treatment for drug abuse. Follow-up outcomes and length of time spent. Arch Gen Psychiatry. 1981;38:875-880.
12. Simpson DD. The relation of time spent in drug abuse treatment to posttreatment outcome. Am J Psychiatry. 1979;136:1449-1453.
13. Simpson DD, Joe GW, Rowan-Szal GA. Drug abuse treatment retention and process effects on follow-up outcomes. Drug Alcohol Depend. 1997;47: 227-235.
14. Kornor H, Waal H. Methadone dose, treatment duration and heroin use in drug-assisted rehabilitation. Tidsskr Nor Laegeforen. 2004;124:332-334.
15. Hargreaves WA. Methadone dosage and duration for maintenance treatment. In: Cooper JR, et al, ed. Research on the Treatment of Narcotic Addiction. State of the Art. Treatment Research Monograph Series. Rockville, MD: NIDA. 1983;19-79.
16. Newman RG. The pharmacological rationale for methadone treatment of narcotic addiction. In: Ta-gliamonte A, Maremmani I, eds. Drug Addiction and Related Clinical Problems. Wien, New York: SpringerVerlag. 1995;109-118.
17. Dole VP, Nyswander ME. Heroin addiction: a metabolic disease. Arch Intern Med. 1967;120:19-24.
18. Dole VP, Kreek MJ. Methadone plasma level: sub-stained by a reservoir of drug in tissue. Proc Natl Acad Sci USA. 1973;70:10-30.
19. Payte JT. Bad patients or bad treatment? Heroin Addict Relat Clin Probl. 2004;6:37-40.
20. Coppel A. Good practice, good results. Maintenance treatment outcomes in France. Heroin Addict Relat Clin Probl. 2005;7:19-24.
21. Magura S, Rosenblum A. Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med. 2001;68:62-74.
22. Bell J. Quality improvement for methadone maintenance treatment. Subst Use Misuse. 2000;35:1735-1756.
23. Amato L, Minozzi S, Davoli M, et al. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev. 2004;18:CD005031.
24. Magura S, Nwakeze PC, Kang SY, et al. Program quality effects on patients outcomes during metha-done maintenance: a study of 17 clinics. Subst Use Misuse. 1999;34:1299-1324.
25. A.P.A. DSM-IV-TR. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association; 2000.
26. Maremmani I, Castrogiovanni P. DAH-Q: Drug Addiction Questionnaire. Pisa: University Press; 1989.
27. Lahmeyer HW, Channon RA, Schlemmer FJ. Psycho-active Substance Abuse. In: Flaherty JA, et al, ed. Psychiatry. Diagnosis & Tgerapy. San Mateo, CA: Appleton & Lange. 1988;182-199.
28. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005;162:1403-1413.
29. Maremmani I, Popovic D. Heroin dependence. In: Maremmani I, ed. The Principles and Practice of Methadone Treatment. Pisa: Pacini Editore Medicina. 2009;21-30.
30. Maremmani I, Pacini M, Lubrano S, et al. Harm reduction and specific treatments for heroin addiction. Different approaches or levels of intervention? An illness-centred perspective. Heroin Addict Relat Clin Probl. 2002;4:5-11.
31. Maremmani I, Pacini M, Lubrano S, et al. When 'enough' is still not 'enough'. Effectiveness of high-dose methadone in the treatment of heroin addiction. Heroin Addict Relat Clin Probl. 2003;5: 17-32.
32. Maremmani I, Barra M, Bignamini E, et al. Clinical foundations for the use of methadone. Italian Consensus Panel on Methadone Treatment. Heroin Addict Relat Clin Probl. 2002;4:19-31.
33. Benyamina A, Stöver H. Barriers to treatment access and informed patient choice in the treatment of opioid dependence in Europe. Heroin Addict Relat Clin Probl. 2012;14:65-80.
34. Stöver H. Assessing the current state of public-health-related outcomes in opioid dependence across Europe: data from the EQUATOR analysis. Heroin Addict Relat Clin Probl. 2012;14:51-64.
35. Fischer G, Nava F, Stöver H. Outcomes of opioid-dependence treatment across Europe: identifying opportunities for improvement. Heroin Addict Relat Clin Probl. 2012;14:39-50.
36. Dale-Perera A, Goulão J, Stöver H. Quality of care provided to patients receiving opioid maintenance treatment in europe: results from the EQUATOR analysis. Heroin Addict Relat Clin Probl. 2012;14: 23-38.
37. Goulão J, Stöver H. The profile of patients, out-of-treatment users and treating physicians involved in opioid maintenance treatment in Europe. Heroin Addict Relat Clin Probl. 2012;14:7-22.
38. Fischer G, Stöver H. Assessing the current state of opioid-dependence treatment across Europe: methodology of the European Quality Audit of Opioid Treatment (EQUATOR) project. Heroin Addict Relat Clin Probl. 2012;14:5-70.